All Drugs and Chemicals

Pharmaceutical Solutions

Hematinics

Antibodies

Immunoglobulins

Liver Extracts

other digestive system malignancies, including esophageal cancer, pancreatic cancer, gallbladder cancer, etc.

RC108 is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.

RC108

Jianmin Fang, Ph.D

lin shen, PHD

A multi-center, open-label, study designed to evaluate the preliminary efficacy, safety and pharmacokinetics of RC108 in patients with c-Me-positive advanced digestive system malignancies.

The primary purpose of this trial is to evaluate the preliminary efficacy, safety and efficacy of RC108 in patients with c-Me positive advanced gastrointestinal malignancies such as gastric, colorectal, esophageal, hepatic, pancreatic and bile duct cancers.

A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of RC108 for Injection in the Treatment of Patients With c-Met-positiveAdvanced Digestive System Malignant Tumor

Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR)

The disease control rate is the proportion of those subjects with complete response, partial response, or stable disease, as defined by Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

DOR is defined as the time from the participant's initial objective response to study drug therapy to disease progression or death, whichever occurs first.

Time to progression will be measured from the first day of study drug until progression.

PFS time is defined as the time from the participant's first dose of RC108 to either the participant's disease progression or death, whichever occurs first.

Duration from date of sub-study registration (or date of screening/pre-screening registration if patient never enrolls in a sub-study) to date of death due to any cause.

Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t)

Maximum observed plasma concentration (Cmax)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor	NCT05628857	Digestive Cance...	RC108	18 Years - 75 Years	RemeGen Co., Ltd.
A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor	NCT05628857	Digestive Cance...	RC108	18 Years - 75 Years	RemeGen Co., Ltd.

Spots Global Cancer Trial Database for rc108

Every month we try and update this database with for rc108 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for rc108

Every month we try and update this database with for rc108 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for rc108 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.